Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm
Authors:
- Harold J. BursteinHBHarold J. Burstein
- Lyndsay N. HarrisLHLyndsay N. Harris
- P. Kelly MarcomPMP. Kelly Marcom
- Rosemary Lambert-FallsRLRosemary Lambert-Falls
- Kathleen HavlinKHKathleen Havlin
- Beth OvermoyerBOBeth Overmoyer
- Robert J. FriedlanderRFRobert J. Friedlander
- Janet GargiuloJGJanet Gargiulo
- Rochelle StrengerRSRochelle Strenger
- Charles L. VogelCVCharles L. Vogel
- Paula D. RyanPRPaula D. Ryan
- Mathew J. EllisMEMathew J. Ellis
- 1 August 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (15) , 2889-2895
Abstract
Purpose: Trastuzumab-based therapy improves survival for women with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer. We conducted a multicenter phase II study to evaluate the efficacy and safety of trastuzumab combined with vinorelbine, and to assess cardiac surveillance algorithms and tumor markers as prognostic tools.Keywords
This publication has 19 references indexed in Scilit:
- Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast CancerThe Oncologist, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- TrastuzumabDrugs, 2002
- New cytotoxic agents and schedules for advanced breast cancerSeminars in Oncology, 2001
- A Review of Vinorelbine in the Treatment of Breast CancerClinical Breast Cancer, 2001
- Fluorescence in situ hybridization (FISH) may accurately identify patients who obtain survival benefit from herceptin plus chemotherapyEuropean Journal of Cancer, 2001
- Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogeneEuropean Journal of Cancer, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- The meaning and use of the area under a receiver operating characteristic (ROC) curve.Radiology, 1982